The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Open Access
- 14 December 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (24), 10038-10043
- https://doi.org/10.1158/0008-5472.can-10-2956
Abstract
The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy. When present in cis with an ALK translocation, this mutation (also detected in neuroblastomas) causes an increase in ALK phosphorylation, cell growth, and downstream signaling. Furthermore, the F1174L mutation inhibits crizotinib-mediated downregulation of ALK signaling and blocks apoptosis in RANBP2-ALK Ba/F3 cells. A chemically distinct ALK inhibitor, TAE684, and the HSP90 inhibitor 17-AAG are both effective in models harboring the F1174L ALK mutation. Our findings highlight the importance of studying drug resistance mechanisms in order to develop effective clinical treatments for patients with ALK-translocated cancers. Cancer Res; 70(24); 10038–43. ©2010 AACR.Keywords
Other Versions
This publication has 22 references indexed in Scilit:
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic TumorNew England Journal of Medicine, 2010
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive InhibitorsBiochemistry, 2010
- A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-Rearranged Lung Adenocarcinomas by Standard ImmunohistochemistryClinical Cancer Research, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- A mouse model for EML4-ALK -positive lung cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALKProceedings of the National Academy of Sciences of the United States of America, 2007
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994